NHS scientists have developed an innovative drug for patients who have incurable cancers.
Medicines called "Enterktinib" are anticancer agents and are able to treat various types of diseases, regardless of their location in the body.
This drug is different from traditional treatments that are based on the site of the tumor. "Enterretinib" becomes the second similar drug that received "green light".
It is noted that the drug is intended for persons aged 12 years, who face rare cancers known as NTRK merger.
"Treatment methods as" Enterktinib "can make revolutionary changes in approaches to cancer treatment, directing them to genetic mutations that activate the tumor growth, regardless of its location," said the scientist with NHS, Mandert Boise.
